Critical Analysis of Baryon Masses and Sigma-Terms in Heavy Baryon Chiral Perturbation Theory

We present an analysis of the octet baryon masses and the $\pi N$ and $KN$ $\sigma$--terms in the framework of heavy baryon chiral perturbation theory. At next-to-leading order, ${\cal O}(q^3)$, knowledge of the baryon masses and $\sigma_{\pi N}(0)$ allows to determine the three corresponding finite low--energy constants and to predict the the two $KN$ $\sigma$--terms $\sigma^{(1,2)}_{KN} (0)$. We also include the spin-3/2 decuplet in the effective theory. The presence of the non--vanishing energy scale due to the octet--decuplet splitting shifts the average octet baryon mass by an infinite amount and leads to infinite renormalizations of the low--energy constants. The first observable effect of the decuplet intermediate states to the baryon masses starts out at order $q^4$. We argue that it is not sufficient to retain only these but no other higher order terms to achieve a consistent description of the three--flavor scalar sector of baryon CHPT. In addition, we critically discuss an SU(2) result which allows to explain the large shift of $\sigma_{\pi N}(2M_\pi^2) - \sigma_{\pi N}(0)$ via intermediate $\Delta (1232)$ states.Comment: 18 pp, TeX, BUTP-93/05 and CRN-93-0

Kaon-Nucleon Scattering Amplitudes and Z∗^*-Enhancements from Quark Born Diagrams

We derive closed form kaon-nucleon scattering amplitudes using the ``quark Born diagram" formalism, which describes the scattering as a single interaction (here the OGE spin-spin term) followed by quark line rearrangement. The low energy I=0 and I=1 S-wave KN phase shifts are in reasonably good agreement with experiment given conventional quark model parameters. For $k_{lab}> 0.7$ Gev however the I=1 elastic phase shift is larger than predicted by Gaussian wavefunctions, and we suggest possible reasons for this discrepancy. Equivalent low energy KN potentials for S-wave scattering are also derived. Finally we consider OGE forces in the related channels K$\Delta$, K$^*$N and K$^*\Delta$, and determine which have attractive interactions and might therefore exhibit strong threshold enhancements or ``Z$^*$-molecule" meson-baryon bound states. We find that the minimum-spin, minimum-isospin channels and two additional K$^*\Delta$ channels are most conducive to the formation of bound states. Related interesting topics for future experimental and theoretical studies of KN interactions are also discussed.Comment: 34 pages, figures available from the authors, revte

Prospects for e+e- physics at Frascati between the phi and the psi

We present a detailed study, done in the framework of the INFN 2006 Roadmap, of the prospects for e+e- physics at the Frascati National Laboratories. The physics case for an e+e- collider running at high luminosity at the phi resonance energy and also reaching a maximum center of mass energy of 2.5 GeV is discussed, together with the specific aspects of a very high luminosity tau-charm factory. Subjects connected to Kaon decay physics are not discussed here, being part of another INFN Roadmap working group. The significance of the project and the impact on INFN are also discussed. All the documentation related to the activities of the working group can be found in http://www.roma1.infn.it/people/bini/roadmap.html.Comment: INFN Roadmap Report: 86 pages, 25 figures, 9 table

Multicenter evaluation of a new chromogenic factor X assay in plasma of patients on oral anticoagulants

A new factor X (FX) assay based on the chromogenic substrate S-2337 was compared with the coagulation screening method Thrombotest (TT) in 1431 plasma samples from 188 patients followed up for 6-8 months on long-term oral anticoagulants. In all the participating laboratories, the results of the methods were highly correlated (P < 0. 001). The FX values corresponding on the regression line to a TT therapeutic interval of 5-15 per cent ranged from 8 to 36 per cent in different laboratories. The results of the two methods were highly concordant in classifying the patients within or outside the therapeutic interval. The precision of the FX method was no better than that of TT both in normal and pathological samples. On the basis of these findings, the FX chromogenic method appears to be a potentially promising new approach to the problem of anticoagulant therapy control, providing that a longitudinal study confirm its clinical suitability

A Systems Medicine Clinical Platform for Understanding and Managing Non- Communicable Diseases

Non-Communicable Diseases (NCDs) are among the most pressing global health problems of the twenty-first century. Their rising incidence and prevalence is linked to severe morbidity and mortality, and they are putting economic and managerial pressure on healthcare systems around the world. Moreover, NCDs are impeding healthy aging by negatively affecting the quality of life of a growing number of the global population. NCDs result from the interaction of various genetic, environmental and habitual factors, and cluster in complex ways, making the complex identification of resulting phenotypes not only difficult, but also a top research priority. The degree of complexity required to interpret large patient datasets generated by advanced high-throughput functional genomics assays has now increased to the point that novel computational biology approaches are essential to extract information that is relevant to the clinical decision-making process. Consequently, system-level models that interpret the interactions between extensive tissues, cellular and molecular measurements and clinical features are also being created to identify new disease phenotypes, so that disease definition and treatment are optimized, and novel therapeutic targets discovered. Likewise, Systems Medicine (SM) platforms applied to extensively-characterized patients provide a basis for more targeted clinical trials, and represent a promising tool to achieve better prevention and patient care, thereby promoting healthy aging globally. The present paper: (1) reviews the novel systems approaches to NCDs; (2) discusses how to move efficiently from Systems Biology to Systems Medicine; and (3) presents the scientific and clinical background of the San Raffaele Systems Medicine Platform